RENASCIENCE INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 346 JPY | -0.29% |
|
-0.86% | -20.28% |
| Sales 2023 | 100M 630K | Sales 2024 | 194M 1.22M | Capitalization | 4.84B 30.52M |
|---|---|---|---|---|---|
| Net income 2023 | -335M -2.11M | Net income 2024 | -258M -1.63M | EV / Sales 2023 | 37.9 x |
| Net cash position 2023 | 1.9B 11.99M | Net cash position 2024 | 1.67B 10.52M | EV / Sales 2024 | 16.4 x |
| P/E ratio 2023 |
-17
x | P/E ratio 2024 |
-18.8
x | Employees | 4 |
| Yield 2023 * |
-
| Yield 2024 |
-
| Free-Float | 48.23% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.29% | ||
| 1 week | -0.86% | ||
| Current month | +1.17% | ||
| 1 month | -8.71% | ||
| 3 months | +1.47% | ||
| 6 months | -18.20% | ||
| Current year | -20.28% |
1 week
342.00
350.00
1 month
330.00422.00
Current year
328.00440.00
1 year
328.00584.00
3 years
282.001 060.00
5 years
282.001 060.00
10 years
282.001 060.00
| Managers | Title | Age | Since |
|---|---|---|---|
Koji Naito
PSD | President | 65 | 18-12-31 |
Sho Kato
CTO | Chief Tech/Sci/R&D Officer | 36 | 18-04-30 |
Kazuhiro Ikeda
ADM | Chief Administrative Officer | 68 | 19-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yasuo Azuma
BRD | Director/Board Member | 76 | 19-03-31 |
Kazuhiro Ikeda
ADM | Chief Administrative Officer | 68 | 19-12-31 |
Toshio Miyata
CHM | Chairman | 63 | 18-03-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-16 | 346 | -0.29% | 12 100 |
| 24-07-12 | 347 | +0.87% | 22,600 |
| 24-07-11 | 344 | -0.58% | 19,500 |
| 24-07-10 | 346 | -0.86% | 21,200 |
| 24-07-09 | 349 | -1.41% | 46,400 |
Delayed Quote Japan Exchange, July 16, 2024 at 12:31 am EDT
More quotes
Renascience Inc is mainly engaged in the development and sale of pharmaceuticals and medical devices. The company is engaged in the research and development of various modalities (pharmaceuticals, medical devices, artificial intelligence (AI) solutions) to solve problems in the medical field, in collaboration with physicians. The Company is engaged in the development of drugs for four non-infectious aging-related diseases: cancer, diabetes, respiratory diseases, and cardiovascular diseases. The Company is also engaged in the solve of other medical issues such as diseases of women and children, and COVID-19 infection.
Sector
Pharmaceuticals
Calendar
2024-08-07
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -20.28% | 27.94M | |
| +63.05% | 856B | |
| +39.42% | 631B | |
| -4.78% | 359B | |
| +17.52% | 325B | |
| +8.43% | 297B | |
| +14.19% | 244B | |
| +5.81% | 234B | |
| +16.77% | 226B | |
| +14.63% | 177B |
- Stock Market
- Equities
- 4889 Stock
